File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The effectiveness of carbamazepine in unipolar depression: A double-blind, randomized, placebo-controlled study

TitleThe effectiveness of carbamazepine in unipolar depression: A double-blind, randomized, placebo-controlled study
Authors
KeywordsCarbamazepine
Clinical trial
Major depressive disorder
Unipolar depression
Issue Date2008
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jad
Citation
Journal Of Affective Disorders, 2008, v. 109 n. 1-2, p. 91-97 How to Cite?
AbstractOur previous studies have shown the effectiveness of carbamazepine (CBZ) in the treatment of bipolar depression. This double-blind, randomized, placebo-controlled study was designed to further evaluate the efficacy of CBZ in unipolar depressed subjects who never received antidepressant and other psychotherapeutic treatment. A total of 89 patients who had at least two major depressive episodes, but never experienced mania or hypomania, were randomly assigned to treatment with immediate-release CBZ 300-800 mg/daily (n = 51) or placebo (n = 38) for 12 weeks. The primary efficacy was measured using the Hamilton Rating Scale for Depression (HAMD), Montgomery-Asberg Depression Rating Scale (MADRS), and Clinical Global Impression-Severity (CGI-S). The mean final CBZ dose of CBZ-treated patients was 461.6 mg/day. CBZ treatment yielded significantly greater improvements on the three efficacy measures at week 8 through endpoint compared to placebo. Patients assigned to CBZ treatment also had a significantly higher clinical response rate than placebo (74% vs. 42%, p < 0.001), as defined for ≥ 50% reduction in HAMD score. Based on the results of our present and previous studies, we suggest that CBZ might be considered an alternative in the management of certain conditions in major depressive disorder. © 2007 Elsevier B.V. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/89663
ISSN
2015 Impact Factor: 3.57
2015 SCImago Journal Rankings: 1.927
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorZhang, ZJen_HK
dc.contributor.authorTan, QRen_HK
dc.contributor.authorTong, Yen_HK
dc.contributor.authorLi, Qen_HK
dc.contributor.authorKang, WHen_HK
dc.contributor.authorZhen, XCen_HK
dc.contributor.authorPost, RMen_HK
dc.date.accessioned2010-09-06T10:00:06Z-
dc.date.available2010-09-06T10:00:06Z-
dc.date.issued2008en_HK
dc.identifier.citationJournal Of Affective Disorders, 2008, v. 109 n. 1-2, p. 91-97en_HK
dc.identifier.issn0165-0327en_HK
dc.identifier.urihttp://hdl.handle.net/10722/89663-
dc.description.abstractOur previous studies have shown the effectiveness of carbamazepine (CBZ) in the treatment of bipolar depression. This double-blind, randomized, placebo-controlled study was designed to further evaluate the efficacy of CBZ in unipolar depressed subjects who never received antidepressant and other psychotherapeutic treatment. A total of 89 patients who had at least two major depressive episodes, but never experienced mania or hypomania, were randomly assigned to treatment with immediate-release CBZ 300-800 mg/daily (n = 51) or placebo (n = 38) for 12 weeks. The primary efficacy was measured using the Hamilton Rating Scale for Depression (HAMD), Montgomery-Asberg Depression Rating Scale (MADRS), and Clinical Global Impression-Severity (CGI-S). The mean final CBZ dose of CBZ-treated patients was 461.6 mg/day. CBZ treatment yielded significantly greater improvements on the three efficacy measures at week 8 through endpoint compared to placebo. Patients assigned to CBZ treatment also had a significantly higher clinical response rate than placebo (74% vs. 42%, p < 0.001), as defined for ≥ 50% reduction in HAMD score. Based on the results of our present and previous studies, we suggest that CBZ might be considered an alternative in the management of certain conditions in major depressive disorder. © 2007 Elsevier B.V. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jaden_HK
dc.relation.ispartofJournal of Affective Disordersen_HK
dc.rightsJournal of Affective Disorders. Copyright © Elsevier BV.en_HK
dc.subjectCarbamazepineen_HK
dc.subjectClinical trialen_HK
dc.subjectMajor depressive disorderen_HK
dc.subjectUnipolar depressionen_HK
dc.titleThe effectiveness of carbamazepine in unipolar depression: A double-blind, randomized, placebo-controlled studyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0165-0327&volume=109&spage=91&epage=97&date=2008&atitle=The+effectiveness+of+carbamazepine+in+unipolar+depression:+a+double-blind,+randomized,+placebo-controlled+study.en_HK
dc.identifier.emailZhang, ZJ: zhangzj@hkucc.hku.hken_HK
dc.identifier.emailTong, Y: tongyao@hku.hken_HK
dc.identifier.authorityZhang, ZJ=rp01297en_HK
dc.identifier.authorityTong, Y=rp00509en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jad.2007.11.004en_HK
dc.identifier.pmid18093662-
dc.identifier.scopuseid_2-s2.0-43949145968en_HK
dc.identifier.hkuros146000en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-43949145968&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume109en_HK
dc.identifier.issue1-2en_HK
dc.identifier.spage91en_HK
dc.identifier.epage97en_HK
dc.identifier.isiWOS:000256987300009-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridZhang, ZJ=8061473900en_HK
dc.identifier.scopusauthoridTan, QR=7102120177en_HK
dc.identifier.scopusauthoridTong, Y=9045384000en_HK
dc.identifier.scopusauthoridLi, Q=36072924100en_HK
dc.identifier.scopusauthoridKang, WH=10143941200en_HK
dc.identifier.scopusauthoridZhen, XC=16246797700en_HK
dc.identifier.scopusauthoridPost, RM=7202218145en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats